David McClung

David McClung, listed as finance chief, appears in our data through filings on BioCardia, Inc. shares, published by SEC (Form 4). We count 16 filings; the first trade dates from 10 June 2021 and the latest from 2 July 2026.

On the market, this insider has only ever bought: 3 purchases, €35k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 13 share grants.

A typical purchase (the median) is worth €8,483. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 7 July 2026 came the latest disclosure, a share grant for €25k in BioCardia, Inc. The last purchase on record was published on 2 July 2025, which is 473 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.